Caxton Corp is based out of Princeton. Their last reported 13F filing for Q4 2023 included $18,524,322 in managed 13F securities
and a top 10 holdings concentration of 99.27%. Caxton Corp's largest holding is Xeris Biopharma Holdings Inc with shares held of 5,641,920. Whalewisdom has at least 50 13F filings, 17 13D filings, and 49 13G filings
Confidential Treatment - This manager
has obtained confidential treatment for one or
more investments in the most recent 13F filing.
2023-12-31
Top Buys (13F)
Name | % Change |
---|---|
SPY SPDR S&P 500 ETF TRU | 3.39% |
BRK.B Berkshire Hathaway I | 1.99% |
ABVX Abivax | 0.97% |
LXEO Lexeo Therapeutics I | 0.75% |
HARP Harpoon Therapeutics | 0.7% |
2023-12-31
Top Sells (13F)
Name | % Change |
---|---|
SVRA Savara Inc | 38.62% |
ACRS Aclaris Therapeutics | 0.51% |
CMPX Compass Therapeutics | 0.28% |
ALLK Allakos Inc | 0.06% |
ELEV Elevation Oncology I | 0.05% |
2023-12-31
13F Holdings Summary
Name | $ Change |
---|---|
XERS Xeris Biopharma Hold | 71.57% |
SVRA Savara Inc | 8.97% |
RZLT Rezolute Inc | 7.07% |
SPY SPDR S&P 500 ETF TRU | 3.39% |
MTEM Molecular Templates | 2.76% |
Confidential Treatment - Holdings omitted in latest filing.
2023-12-31
13F Activity
Market Value | $18.5m, Prior: $26.3m |
New Purchases | 5 stocks |
Added To | 0 stocks |
Sold out of | 2 stocks |
Reduced holdings in | 4 stocks |
Top 10 Holdings % | 99.27% |
Turnover %[1] | 58.33% |
Turnover Alt %[2] | 7.8% |
Time Held Top 20 | 5.4167 quarters |
Time Held Top 10 | 3.5 quarters |
Time Held All | 5.42 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2023-12-31
13F Sector Allocation Over Time
2023-12-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2023-12-31